-
Je něco špatně v tomto záznamu ?
Clinical manifestation of mitochondrial diseases
M. Magner, H. Kolářová, T. Honzik, I. Švandová, J. Zeman,
Jazyk angličtina Země Polsko
Typ dokumentu časopisecké články, přehledy
Grantová podpora
NT14156
MZ0
CEP - Centrální evidence projektů
NLK
Medline Complete (EBSCOhost)
od 2014-01-01 do 2019-10-27
Medline Complete (EBSCOhost)
od 2014-04-01 do 2019-10-31
ROAD: Directory of Open Access Scholarly Resources
od 2011 do 2019
PubMed
26982751
Knihovny.cz E-zdroje
- MeSH
- elektroencefalografie MeSH
- Kearnsův-Sayreův syndrom diagnóza patofyziologie MeSH
- lidé MeSH
- mitochondriální DNA analýza MeSH
- mitochondriální encefalomyopatie diagnóza patofyziologie MeSH
- mitochondriální myopatie diagnóza patofyziologie MeSH
- mitochondriální nemoci diagnóza patofyziologie MeSH
- mozek patofyziologie MeSH
- syndrom MELAS diagnóza patofyziologie MeSH
- syndrom MERRF diagnóza patofyziologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Mitochondrial disorders (MD) represent a clinically, biochemically and genetically heterogeneous group of diseases associated with dysfunction of the oxidative phosphorylation system and pyruvate dehydrogenase complex. Our aim was to illustrate the most common clinical presentation of MD on the example of selected diseases and syndromes. The minimal prevalence of MD is estimated as 1 to 5,000. MD may manifest at any age since birth until late-adulthood with acute manifestation or as a chronic progressive disease. Virtually any organ may be impaired, but the organs with the highest energetic demands are most frequently involved, including brain, muscle, heart and liver. Some MD may manifest as a characteristic cluster of clinical features (e.g. MELAS syndrome, Kearns-Sayre syndrome). Diagnostics includes detailed history, the comprehensive clinical examination, results of specialized examinations (especially cardiology, visual fundus examination, brain imaging, EMG), laboratory testing of body fluids (lactate, aminoacids, organic acids), and analysis of bioptic samples of muscle, skin, and liver, eventually. Normal lactate level in blood does not exclude the possibility of MD. Although the aimed molecular genetic analyses may be indicated in some of mitochondrial diseases, the methods of next generation sequencing come into focus. Examples of treatment are arginine supplementation in MELAS syndrome, ketogenic diet in pyruvate oxidation disorders or quinone analogs in patients with LHON. Conclusion: The clinical suspicion of a mitochondrial disorder is often delayed, or the disease remains undiagnosed. The correct diagnosis and adequate treatment can improve prognosis of the patient. Access to genetic counseling is also of great importance.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16021008
- 003
- CZ-PrNML
- 005
- 20190902103152.0
- 007
- ta
- 008
- 160722s2015 pl f 000 0|eng||
- 009
- AR
- 035 __
- $a (PubMed)26982751
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a pl
- 100 1_
- $a Magner, Martin $7 xx0084624
- 245 10
- $a Clinical manifestation of mitochondrial diseases / $c M. Magner, H. Kolářová, T. Honzik, I. Švandová, J. Zeman,
- 520 9_
- $a Mitochondrial disorders (MD) represent a clinically, biochemically and genetically heterogeneous group of diseases associated with dysfunction of the oxidative phosphorylation system and pyruvate dehydrogenase complex. Our aim was to illustrate the most common clinical presentation of MD on the example of selected diseases and syndromes. The minimal prevalence of MD is estimated as 1 to 5,000. MD may manifest at any age since birth until late-adulthood with acute manifestation or as a chronic progressive disease. Virtually any organ may be impaired, but the organs with the highest energetic demands are most frequently involved, including brain, muscle, heart and liver. Some MD may manifest as a characteristic cluster of clinical features (e.g. MELAS syndrome, Kearns-Sayre syndrome). Diagnostics includes detailed history, the comprehensive clinical examination, results of specialized examinations (especially cardiology, visual fundus examination, brain imaging, EMG), laboratory testing of body fluids (lactate, aminoacids, organic acids), and analysis of bioptic samples of muscle, skin, and liver, eventually. Normal lactate level in blood does not exclude the possibility of MD. Although the aimed molecular genetic analyses may be indicated in some of mitochondrial diseases, the methods of next generation sequencing come into focus. Examples of treatment are arginine supplementation in MELAS syndrome, ketogenic diet in pyruvate oxidation disorders or quinone analogs in patients with LHON. Conclusion: The clinical suspicion of a mitochondrial disorder is often delayed, or the disease remains undiagnosed. The correct diagnosis and adequate treatment can improve prognosis of the patient. Access to genetic counseling is also of great importance.
- 650 _2
- $a mozek $x patofyziologie $7 D001921
- 650 _2
- $a mitochondriální DNA $x analýza $7 D004272
- 650 _2
- $a elektroencefalografie $7 D004569
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Kearnsův-Sayreův syndrom $x diagnóza $x patofyziologie $7 D007625
- 650 _2
- $a syndrom MELAS $x diagnóza $x patofyziologie $7 D017241
- 650 _2
- $a syndrom MERRF $x diagnóza $x patofyziologie $7 D017243
- 650 _2
- $a mitochondriální nemoci $x diagnóza $x patofyziologie $7 D028361
- 650 _2
- $a mitochondriální encefalomyopatie $x diagnóza $x patofyziologie $7 D017237
- 650 _2
- $a mitochondriální myopatie $x diagnóza $x patofyziologie $7 D017240
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kolářová, Hana $7 xx0227560
- 700 1_
- $a Honzík, Tomáš $7 xx0075651
- 700 1_
- $a Švandová, Ivana
- 700 1_
- $a Zeman, Jiří $u Department of Paediatrics and Adolescent Medicine, Ke Karlovu 2, 128 08 Praha 2, Czech Republic
- 773 0_
- $w MED00189519 $t Developmental period medicine $x 1428-345X $g Roč. 19, č. 4 (2015), s. 441-449
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26982751 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20190902103520 $b ABA008
- 999 __
- $a ok $b bmc $g 1155678 $s 945536
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 19 $c 4 $d 441-449 $i 1428-345X $m Developmental period medicine $n Dev Period Med $x MED00189519
- GRA __
- $a NT14156 $p MZ0
- LZP __
- $a Pubmed-20160722